Invention Grant
- Patent Title: Extracellular histones as biomarkers for prognosis and molecular targets for therapy
-
Application No.: US16263124Application Date: 2019-01-31
-
Publication No.: US11458187B2Publication Date: 2022-10-04
- Inventor: Charles T. Esmon , Jun Xu , Xiaomei Zhang
- Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATION
- Applicant Address: US OK Oklahoma City
- Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATION
- Current Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATION
- Current Assignee Address: US OK Oklahoma City
- Agency: ParkerHighlander, PLLC
- Main IPC: A61K38/10
- IPC: A61K38/10 ; A61K39/395 ; A61K31/727 ; A61K38/17 ; A61K38/48 ; A61K45/06 ; C07K16/18 ; C07K16/40 ; G01N33/68 ; A61K38/36 ; C07K7/08 ; A61K39/00

Abstract:
Hyper-inflammatory responses can lead to a variety of diseases including sepsis. It is now shown that extracellular histones released in response to inflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death during sepsis. As such, they can be targeted pharmacologically by inhibitors, as well as used as biomarkers for prognosis of sepsis and other diseases.
Public/Granted literature
- US20190216884A1 EXTRACELLULAR HISTONES AS BIOMARKERS FOR PROGNOSIS AND MOLECULAR TARGETS FOR THERAPY Public/Granted day:2019-07-18
Information query
IPC分类: